Immunotherapy in lung cancer

Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become st...

Full description

Saved in:
Bibliographic Details
Published inJournal of surgical oncology Vol. 123; no. 3; pp. 718 - 729
Main Authors Montenegro, Gabriela Bravo, Farid, Saira, Liu, Stephen V.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2021
Subjects
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - immunology
checkpoint inhibitors
chemo‐immunotherapy
Clinical Trials, Phase III as Topic
Humans
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Immunotherapy - methods
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - therapy
Monoclonal antibodies
neoadjuvant
Oncology
PD‐1
PD‐L1
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Randomized Controlled Trials as Topic
PD-L1
neoadjuvant
chemo-immunotherapy
PD-1
checkpoint inhibitors
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier‐stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26347